Axium Healthcare Puerto Rico is Now Dispensing REZLIDHIA™
Rigel Pharmaceuticals has selected Axium Healthcare as their exclusive Specialty Pharmacy for the Puerto Rico market to dispense REZLIDHIA™ for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML), in adults.
Axium Healthcare is proud to announce it is now dispensing REZLIDHIA (olutasidenib) capsules, for oral use treatment and is indicated:
- Is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for relapsed or refractory acute myeloid leukemia (AML) for adult patients with a susceptible IDH1 mutation as detected by an FDA-approved test.
Milton Latoni, VP of Sales & Business Development for Axium Healthcare Puerto Rico, recently shared what access to REZLIDHIA means for oncology patients in PR. “At Axium Healthcare, Oncology has always been a key focus and we’re privileged to incorporate another limited distribution drug to our portfolio. Working closely with pharmaceutical partners allows us to gain access to therapies that become available to patients in PR with the local service the island requires. As the second Rigel FDA-approved therapy we have access to (TAVALISSE was the first), we are proud to add REZLIDHIA to our treatment options for patients with a unique AML mutation.”
At Axium Healthcare our clinical and care teams have extensive experience with the treatment challenges that can arise when dealing with Oncology. We are passionate about simplifying the enrollment process for our patients by providing comprehensive financial services and personalized patient care support.
Axium Healthcare:
At Axium Healthcare, our mission is to be the preferred pharmacy for people undergoing complex medication therapies by optimizing clinical outcomes and providing a high-touch, caring experience. As a leading specialty pharmacy, Axium Healthcare offers comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Dermatology, HIV, Hepatitis C, Oncology, Multiple Sclerosis, Movement Disorders, Rheumatoid Arthritis, Growth Hormone Deficiency, Hunters Syndrome, Hemophilia, IVIG, Rare Diseases plus others. Axium Healthcare services patients island-wide and is ACHC (since 2010) and URAC Accredited (since 2016). Axium Healthcare's clinically effective and cost-efficient therapy management programs provide direct value to healthcare organizations nationwide. We blend a high-touch, caring patient experience with specialized clinical knowledge, personalized care programs, and administrative expertise. For more information, visit www.axiumpr.com.
About Rigel Pharmaceuticals:
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
REZLIDHIA™ is a registered trademarks of Rigel Pharmaceuticals Inc. Any other trademarks referred to in this release are the property of their respective owners.